364 related articles for article (PubMed ID: 22820499)
1. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.
Lu W; Lin C; King TD; Chen H; Reynolds RC; Li Y
Cell Signal; 2012 Dec; 24(12):2291-6. PubMed ID: 22820499
[TBL] [Abstract][Full Text] [Related]
2. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
3. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.
Lu W; Lin C; Li Y
Cell Signal; 2014 Jun; 26(6):1303-9. PubMed ID: 24607787
[TBL] [Abstract][Full Text] [Related]
4. Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells.
Yu S; Wang Z; Su Z; Song J; Zhou L; Sun Q; Liu S; Li S; Li Y; Wang M; Zhang GQ; Zhang X; Liu ZJ; Lu D
BMC Complement Altern Med; 2018 Feb; 18(1):59. PubMed ID: 29444668
[TBL] [Abstract][Full Text] [Related]
5. Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells.
Lu W; Li Y
J Cell Biochem; 2014 Oct; 115(10):1799-807. PubMed ID: 24905570
[TBL] [Abstract][Full Text] [Related]
6.
Chen LJ; Lin XX; Guo J; Xu Y; Zhang SX; Chen D; Zhao Q; Xiao J; Lian GH; Peng SF; Guo D; Yang H; Shu Y; Zhou HH; Zhang W; Chen Y
Int J Biol Sci; 2021; 17(14):3936-3953. PubMed ID: 34671210
[No Abstract] [Full Text] [Related]
7. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.
Kaur M; Velmurugan B; Tyagi A; Agarwal C; Singh RP; Agarwal R
Neoplasia; 2010 May; 12(5):415-24. PubMed ID: 20454513
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine-based signal mediates LRP6 receptor endocytosis and desensitization of Wnt/β-catenin pathway signaling.
Liu CC; Kanekiyo T; Roth B; Bu G
J Biol Chem; 2014 Oct; 289(40):27562-70. PubMed ID: 25143377
[TBL] [Abstract][Full Text] [Related]
9. Transmembrane protein 97 exhibits oncogenic properties via enhancing LRP6-mediated Wnt signaling in breast cancer.
Zhu H; Su Z; Ning J; Zhou L; Tan L; Sayed S; Song J; Wang Z; Li H; Sun Q; Liu S; Sha O; Leng F; Chen X; Lu D
Cell Death Dis; 2021 Oct; 12(10):912. PubMed ID: 34615853
[TBL] [Abstract][Full Text] [Related]
10. The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.
Lin C; Lu W; Zhang W; Londoño-Joshi AI; Buchsbaum DJ; Bu G; Li Y
PLoS One; 2013; 8(2):e58102. PubMed ID: 23469146
[TBL] [Abstract][Full Text] [Related]
11. Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.
Lin C; Lu W; Zhai L; Bethea T; Berry K; Qu Z; Waud WR; Li Y
FEBS Lett; 2011 Oct; 585(19):3120-5. PubMed ID: 21907199
[TBL] [Abstract][Full Text] [Related]
12. CDDO-Me Elicits Anti-Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex.
Zhou L; Wang Z; Yu S; Xiong Y; Fan J; Lyu Y; Su Z; Song J; Liu S; Sun Q; Lu D
J Pharmacol Exp Ther; 2020 Apr; 373(1):149-159. PubMed ID: 32015160
[TBL] [Abstract][Full Text] [Related]
13. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
Lu W; Liu CC; Thottassery JV; Bu G; Li Y
Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
[TBL] [Abstract][Full Text] [Related]
14. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.
Wang Z; Li B; Zhou L; Yu S; Su Z; Song J; Sun Q; Sha O; Wang X; Jiang W; Willert K; Wei L; Carson DA; Lu D
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13150-13155. PubMed ID: 27799526
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine phosphorylation of LRP6 by Src and Fer inhibits Wnt/β-catenin signalling.
Chen Q; Su Y; Wesslowski J; Hagemann AI; Ramialison M; Wittbrodt J; Scholpp S; Davidson G
EMBO Rep; 2014 Dec; 15(12):1254-67. PubMed ID: 25391905
[TBL] [Abstract][Full Text] [Related]
16. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.
Wang H; He L; Ma F; Regan MM; Balk SP; Richardson AL; Yuan X
J Biol Chem; 2013 Mar; 288(9):6478-87. PubMed ID: 23306204
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin inhibits Wnt co-receptor, Lrp6, phosphorylation and β-catenin signaling.
Reinke L; Lam AP; Flozak AS; Varga J; Gottardi CJ
Biochem Biophys Res Commun; 2016 Feb; 470(3):606-612. PubMed ID: 26797284
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
[TBL] [Abstract][Full Text] [Related]
19. β-Catenin-dependent pathway activation by both promiscuous "canonical" WNT3a-, and specific "noncanonical" WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency.
Ring L; Neth P; Weber C; Steffens S; Faussner A
Cell Signal; 2014 Feb; 26(2):260-7. PubMed ID: 24269653
[TBL] [Abstract][Full Text] [Related]
20. Receptor heterodimerization as a novel mechanism for the regulation of Wnt/β-catenin signaling.
Lee K; Shin Y; Cheng R; Park K; Hu Y; McBride J; He X; Takahashi Y; Ma JX
J Cell Sci; 2014 Nov; 127(Pt 22):4857-69. PubMed ID: 25271056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
